<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062322</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000304720</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>FCCC-02613</secondary_id>
    <nct_id>NCT00062322</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of Preoperative Chemo/Radiation (Concurrent Irinotecan/Cisplatin/RT) Followed by Surgery in Limited Stage Small Cell Lung Cancer (SCLC-LS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Radiation therapy uses&#xD;
      high-energy x-rays to damage tumor cells. Irinotecan and cisplatin may also make the tumor&#xD;
      cells more sensitive to radiation therapy. Combining chemotherapy with radiation therapy&#xD;
      before surgery may shrink the tumor so that it can be removed during surgery.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of neoadjuvant radiation therapy&#xD;
      given together with irinotecan and cisplatin followed by surgery in treating patients with&#xD;
      limited-stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and feasibility of neoadjuvant chemoradiotherapy with irinotecan&#xD;
           and cisplatin followed by surgery in patients with limited stage small cell lung cancer.&#xD;
&#xD;
        -  Determine the pathologic complete response rate of patients treated with this regimen.&#xD;
&#xD;
        -  Correlate the level of vascular endothelial growth factor with treatment response and&#xD;
           disease outcome in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate genetic polymorphisms in cytochrome P450 1A1, glutathione S-transferase M1 and&#xD;
           P1, myeloperoxidase, and NAD(p)H: quinone oxidoreductase with treatment response and&#xD;
           disease outcome in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Induction chemotherapy: Patients receive cisplatin IV over 1 hour on day 1 and&#xD;
           irinotecan IV over 90 minutes on days 1 and 8.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning on day 21, patients receive chemoradiotherapy comprising&#xD;
           radiotherapy once daily, 5 days a week for 4 weeks and then twice daily for 4 days.&#xD;
           Patients also receive cisplatin IV and irinotecan IV over 30-60 minutes once weekly&#xD;
           concurrently with radiotherapy. Treatment continues in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      At the completion of chemoradiotherapy, patients are evaluated for surgery. Patients who are&#xD;
      candidates for surgery receive one additional course of cisplatin IV and irinotecan IV.&#xD;
      Patients who are not candidates for surgery receive radiotherapy twice daily for 4 days and&#xD;
      cisplatin IV and irinotecan IV as in chemoradiotherapy.&#xD;
&#xD;
        -  Surgery: Approximately 2-4 weeks after the last dose of chemotherapy, patients undergo&#xD;
           surgery.&#xD;
&#xD;
      Patients are followed every 4 months for 2 years and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed small cell lung cancer&#xD;
&#xD;
               -  Limited stage disease (clinical stage I-IIIA) and meets the following criteria:&#xD;
&#xD;
                    -  Confined to 1 hemithorax&#xD;
&#xD;
                    -  No T4 disease based on malignant pleural effusion&#xD;
&#xD;
                    -  No N3 disease based on contralateral hilar or supraclavicular involvement&#xD;
&#xD;
               -  Contralateral mediastinal (N3) nodes greater than 1.5 cm on CT scan must be&#xD;
                  biopsied to rule out pathologic involvement&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Tumor must be able to be encompassed by limited radiotherapy field without&#xD;
             significantly compromising pulmonary function&#xD;
&#xD;
          -  No pleural effusion visible on chest x-ray (regardless of cytology)&#xD;
&#xD;
          -  No prior complete tumor resection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,800/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  No known Gilbert's disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Calcium less than 12.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
          -  No active unstable angina&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Calculated postoperative FEV_1 at least 800 cc&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease with FEV_1 no greater than 1 L or&#xD;
             uncontrolled bronchospasm in the unaffected lung&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 2 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or any other noninvasive&#xD;
             malignancy&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No history of uncontrolled psychiatric illness that would preclude giving informed&#xD;
             consent or complying with study&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus (random blood sugar at least 250 mg/dL)&#xD;
&#xD;
          -  No other concurrent serious medical illness&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  No prior topotecan&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the chest or other areas containing 30% or more of&#xD;
             marrow-bearing bone&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent phenytoin, phenobarbital, or other antiepileptic prophylactic drugs&#xD;
&#xD;
          -  No concurrent amifostine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Feigenberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2010</last_update_posted>
  <keyword>limited stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

